• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review - Product Image

Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review

  • Published: March 2013
  • Region: Global
  • 50 pages
  • GlobalData

FEATURED COMPANIES

  • Actavis, Inc.
  • Kali Laboratories, Inc.
  • MORE

Summary

Valeant Pharmaceuticals International, Inc. (Valeant), formerly Biovail Corporation, is a specialty pharmaceutical company developing, manufacturing and marketing of a wide range of specialty, over the counter and generic pharmaceutical products. The product portfolio of the company includes specialty pharmaceuticals across various therapeutic areas; over the counter drugs; and generic pharmaceuticals. It offers dermatology, dentistry, ophthalmology, and neurology and other products. The company operates in US and Puerto Rico, Canada, Poland, Mexico, Brazil and Other geographies worldwide.

Valeant Pharmaceuticals International, Inc. Key Recent Developments

Feb 28, 2013: Valeant Pharma Reports Revenue Of $3.5 Billion In 2012
Jan 03, 2013: Valeant Pharma Appoints Laizer Kornwasser As Chairman
Nov 02, 2012: Valeant Pharma Reports Revenue Of $884.1m In Q3 2012
Sep 13, 2012: Valeant Pharma Announces Resignation Of Rajiv De Silva As COO
Aug 02, 2012: Valeant Pharma Reports Revenue Of $820.1m In Q2 2012

This comprehensive SWOT profile of Valeant Pharmaceuticals International, Inc. provides you an in-depth strategic SWOT analysis of the company’s READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
Valeant Pharmaceuticals International, Inc. - Key Facts
Valeant Pharmaceuticals International, Inc. - Key Employees
Valeant Pharmaceuticals International, Inc. - Key Employee Biographies
Valeant Pharmaceuticals International, Inc. - Major Products and Services
Valeant Pharmaceuticals International, Inc. - Pharmaceutical Pipeline Products Data
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc. - History
Valeant Pharmaceuticals International, Inc. - Company Statement
Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Valeant Pharmaceuticals International, Inc. - Key Manufacturing Facilities
Section 2 – Company Analysis
Valeant Pharmaceuticals International, Inc. - Business Description
Valeant Pharmaceuticals International, Inc. - Corporate Strategy
Valeant Pharmaceuticals International, Inc. - SWOT Analysis
SWOT Analysis - Overview
Valeant Pharmaceuticals International, Inc. - Strengths
Strength - Diversified Product Portfolio
Strength - Focus on Research & Development
Strength - Strategic Merger Agreement
Valeant Pharmaceuticals International, Inc. - Weaknesses
Weakness - Dependence on Major Customers
Weakness - Legal Issues
Valeant Pharmaceuticals International, Inc. - Opportunities
Opportunity - Inorganic Growth Initiatives
Opportunity - Global Dermatology Market
Opportunity - Market Potential - Central Nervous System
Valeant Pharmaceuticals International, Inc. - Threats
Threat - Stringent Government Regulations
Threat - Uncertainties in R&D
Threat - Intense Competition
Valeant Pharmaceuticals International, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Valeant Pharmaceuticals International, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Valeant Pharmaceuticals International, Inc., Recent Developments
Feb 28, 2013: Valeant Pharma Reports Revenue Of $3.5 Billion In 2012
Jan 03, 2013: Valeant Pharma Appoints Laizer Kornwasser As Chairman
Nov 02, 2012: Valeant Pharma Reports Revenue Of $884.1m In Q3 2012
Sep 13, 2012: Valeant Pharma Announces Resignation Of Rajiv De Silva As COO
Aug 02, 2012: Valeant Pharma Reports Revenue Of $820.1m In Q2 2012
May 03, 2012: Valeant Pharma Reports Revenue Of $856.1m Q1 2012 Results
Apr 03, 2012: Valeant To Move Global Head Office To Quebec And Establish New Center Of Excellence In Dermatology
Feb 27, 2012: Valeant Pharma Reports Revenue Of $688.5m Q4 2011 Results
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Valeant Pharmaceuticals International, Inc., Key Facts
Valeant Pharmaceuticals International, Inc., Key Employees
Valeant Pharmaceuticals International, Inc., Key Employee Biographies
Valeant Pharmaceuticals International, Inc., Major Products and Services
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Number of Pipeline Products by Development Stage
Valeant Pharmaceuticals International, Inc., Pipeline Products By Therapy Area and Development Phase
Valeant Pharmaceuticals International, Inc., History
Valeant Pharmaceuticals International, Inc., Other Locations
Valeant Pharmaceuticals International, Inc., Subsidiaries
Valeant Pharmaceuticals International, Inc., Key Manufacturing Facilities
Valeant Pharmaceuticals International, Inc., Key Competitors
Valeant Pharmaceuticals International, Inc., Ratios based on current share price
Valeant Pharmaceuticals International, Inc., Annual Ratios
Valeant Pharmaceuticals International, Inc., Interim Ratios
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Valeant Pharmaceuticals International, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Valeant Pharmaceuticals International, Inc., Pipeline Products by Therapy Area
Valeant Pharmaceuticals International, Inc., Pipeline Products by Development Phase
Valeant Pharmaceuticals International, Inc., Performance Chart (2008 - 2012)
Valeant Pharmaceuticals International, Inc., Ratio Charts
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Valeant Pharmaceuticals International, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Kali Laboratories, Inc.
Teva Pharmaceutical Industries Limited
Actavis, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS